Gilbert Matthew P, Pratley Richard E
Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, Vermont 05405, USA.
Eur J Intern Med. 2009 Jul;20 Suppl 2:S309-18. doi: 10.1016/j.ejim.2009.05.011. Epub 2009 Jun 21.
This article aims to provide an overview of efficacy and safety data on glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus. Our goal is to differentiate the clinical profiles of GLP-1 receptor agonists and DPP-4 inhibitors, as well as the individual agents within each class. Additionally, we examine the utility of GLP-1 receptor agonists and DPP-4 inhibitors as these agents may be applied at different stages of type 2 diabetes therapy and discuss recently published clinical findings and their implications for treatment.
